论文部分内容阅读
目的观察补康灵联合GP方案治疗老年晚期非小细胞肺癌的疗效和不良反应。方法将82例晚期非小细胞肺癌患者随机分为治疗组43例,对照组39例。两组均给予GP方案化疗,21 d为1个疗程。对照组只化疗,治疗组在化疗基础上,于化疗前1周开始口服补康灵50 ml/次,2次/d,直至化疗结束后1周。用药2个疗程后观察近期疗效、不良反应、免疫功能及生存质量的改善情况。结果治疗组有效率(46.51%)略优于对照组(41.03%),但差异无统计学意义(P>0.05);治疗组骨髓抑制、疲劳发生率均低于对照组(P<0.05);治疗组治疗前后CD3+、CD4+、CD4+/CD8+无显著变化(P>0.05),对照组较治疗前降低(P<0.05),两组治疗后比较差异有统计学意义(P<0.05);治疗组生存质量改善率为69.2%优于对照组的45.5%(P<0.05)。结论补康灵联合GP方案治疗非小细胞肺癌能提高患者生存质量,减轻化疗的毒副反应。
Objective To observe the efficacy and adverse reactions of Bukangling combined with GP regimen in the treatment of elderly patients with advanced non-small cell lung cancer. Methods Eighty-two patients with advanced non-small cell lung cancer were randomly divided into treatment group (n = 43) and control group (n = 39). Two groups were given GP chemotherapy, 21 d for a course of treatment. The control group only chemotherapy, the treatment group on the basis of chemotherapy, 1 week before chemotherapy began to take Bukangling 50 ml / time, 2 times / d, until the end of 1 week after chemotherapy. After 2 courses of treatment observed the short-term efficacy, adverse reactions, immune function and quality of life improvement. Results The effective rate (46.51%) in the treatment group was slightly better than that in the control group (41.03%), but the difference was not statistically significant (P> 0.05). The bone marrow suppression and the incidence of fatigue in the treatment group were lower than those in the control group (P <0.05). There was no significant difference in the levels of CD3 +, CD4 + and CD4 + / CD8 between the two groups before and after treatment (P> 0.05), but the difference between the two groups was statistically significant (P <0.05) The quality of life improvement rate was 69.2%, which was better than 45.5% of the control group (P <0.05). Conclusion Bukangling combined with GP regimen in the treatment of non-small cell lung cancer can improve the quality of life of patients and reduce the side effects of chemotherapy.